drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Replicating arenavirus-based therapeutic cancer vaccine (viral vector) encoding HPV16 E6/E7 that infects antigen-presenting cells to induce strong HPV16-specific CD8+ T-cell responses; used in alternating prime-boost with HB-202.
nci_thesaurus_concept_id
C167349
nci_thesaurus_preferred_term
HPV E6/E7-encoding Arenavirus Vaccine HB-201
nci_thesaurus_definition
A cancer vaccine consisting of a replication-attenuated arenavirus lymphocytic choriomeningitis virus (LCMV) encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV E6/E7-encoding arenavirus vaccine HB-201 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
drug_category
VIRAL VECTOR VACCINE
drug_class
Vaccine
drug_delivery_route
Intravenous
drug_mechanism_of_action
Replication-attenuated arenavirus vector encoding HPV16 E6/E7 infects antigen-presenting cells, driving expression and presentation of E6/E7 antigens to elicit strong HPV16-specific CD8+ cytotoxic T-cell responses that target and kill HPV16-expressing tumor cells; can be used in alternating prime-boost with HB-202 to mitigate anti-vector immunity.
drug_name
HB-201
nct_id_drug_ref
NCT05108870